Entresto · DIN 02446936 · 48.6 mg & 51.4 mg · tablet
Limited Use, Reason for Use code 497 requiredMarketed · checked November 19, 2026
StatusLimited Use, Reason for Use code 497 required
Write on scriptReason for Use code 497 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 497
Reason for Use code 497
For the treatment of heart failure (HF) with reduced ejection fraction in patients with New York Heart Association (NYHA) class II or III HF to reduce the incidence of cardiovascular (CV) death and HF hospitalization, if all of the following clinical criteria are met:
- Reduced left ventricular ejection fraction (LVEF) (Less than 40%);
- Patient has NYHA class II to III symptoms despite at least four weeks of treatment with a stable dose of an angiotensin-converting enzyme inhibitor (ACEI) or an angiotensin II receptor antagonist (ARB); and
- In combination with a beta blocker and other recommended therapies, including an aldosterone antagonist (if tolerable).
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Entresto · DIN 02446936
Manufacturer: Novartis Pharma Canada Inc.; listing date 2017-04-27
Health Canada: Marketed since 2016-08-04 · brand ENTRESTO · ATC C09DX04 VALSARTAN AND SACUBITRIL · form Tablet · route Oral · ingredients SACUBITRIL (SACUBITRIL VALSARTAN SODIUM HYDRATE COMPLEX) 49 MG, VALSARTAN (SACUBITRIL VALSARTAN SODIUM HYDRATE COMPLEX) 51 MG · company Novartis pharmaceuticals canada inc · schedule Prescription
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02446936)
Source record
DIN 02446936: Entresto
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 243208003; group id 375; item number 0894; lccId 00283; manufacturer id NOV
Source form: Tab; strength: 48.6mg & 51.4mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $3.7060; ministry $1.8530
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02446936
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93250
Interchangeable products
PMS-Sacubitril-Valsartan · DIN 02564440 · $1.8530
Sandoz Sacubitril-Valsartan · DIN 02549026 · $1.8530
Shortage status: not checked (no credentials)